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Introduction
In the world, the social environment and lifestyle are changing, 
and then diabetic patients has been increasing rapidly.1 Diabetes is a 
significant risk factor for ischemic heart disease due to arteriosclerosis. 
Therefore, myocardial ischemia, angina and myocardial infarction 
may develop and lead to heart failure.2 It means the combination of 
metabolic and cardiovascular diseases, resulting in a serious situation. 
In fact, the prevalence of diabetes with heart failure patients is 
increasing. There was the Japanese Cardiac Registry of Heart Failure 
in Cardiology (JCARE-CARD) study with randomly selected 1677 
patients.3 According to the JCARE-CARD survey, the ratio of diabetes 
with heart failure was 30% and it increased to 44% associated with 
acute heart failure.
On the other hand, β-blockers are widely used in clinical settings 
and their effects are known.4 β-blockers for diabetics have long 
been controversial.5 The reasons include that the adverse effects on 
glucose metabolism and the subjective symptoms of hypoglycemia 
are difficult to detect. However, the effect of heart failure and 
improvement of prognosis seems to be greater than the disadvantage, 
and then β-blockers for diabetes have not been so limited.6 This article 
describes the effects of β-blockers on these subjects based on previous 
evidence. 
Diabetes mellitus with hypoglycemia leads to cardiovascular 
events due to increased stimulation of sympathetic nerves. If this 
response is suppressed by β-blockers, it may have a protective effect 
on the cardiovascular system.7 A sub-analysis of the ACCORD study 
was performed and reported the differences in the use of β-blockers.8 
Those who took β-blockers had significantly suppressed cardiovascular 
events in the strict glycemic control group compared to the standard 
group. Overall mortality was not increasing and administration of 
β-blockers appeared to be beneficial. However, in the ACCORD trial, 
the number of heart failure complications at the time of enrollment 
was low at about 6%, and then discussion is still necessary.
  There was another study from the data of US National Health 
and Nutrition Examination Survey 1999- 2010.9 The relationship 
was investigated between use of β-blockers and all-cause mortality 
in patients with diabetes (n=28409) and without diabetes (n=14,684). 
As a result, DM with β-blockers showed Hazard Ratio (HR) 1.60 
compared to no meds, DM and coronary heart disease (CHD) with 
β-blockers showed HR 1.64 compared to no meds, and non-DM with 
b-blockers showed Hazard Ratio (HR) 0.68 compared to no meds. 
Several factors are involved in these data with necessary discussion. 
In recent years, Sodium-glucose Cotransporter-2 Inhibitors 
(SGLT2i) have been widely used in clinical practice.10 From 
the evidence of these clinical trials, it is possible to suggest the 
pathophysiological situations of diabetes and heart failure. The 
following three studies are compared and summarized in Table 1. 
There was The Empagliflozin Cardiovascular Outcome Event Trial 
in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose 
(EMPA-REG OUTCOME) trial. It targets diabetic patients with 
cardiovascular disease.11 Initially 10.1% of the participants had heart 
failure. However, its criteria for heart failure were not so clear, and 
then it seems that more cases with heart failure may be included.12 For 
the treatment group vs control group, the usage rate of β-blockers was 
65.2% vs. 64.2%, which were rather low. One reason is considered to 
be the wide range of target patients and the low rate of heart failure.
The subjects of the Canagliflozin cardioVascular Assessment Study 
(CANVAS) are diabetic patients with a history of cardiovascular 
disease or high risk of diabetes.13 Canagliflozin was administered to 
10142 subjects, and the effect was examined. Initially, heart failure 
was associated with 14.4% and β-blockers in 70.4%. On the other 
hand, β-blockers were administered at 50.6% in cases without heart 
failure.
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Abstract
Patients with diabetes and heart failure have been increasing due to Japanese Cardiac 
Registry of Heart Failure in Cardiology (JCARE-CARD) study. β-blockers showed 
significantly suppressed cardiovascular events in the strict glycemic control group. Sodium-
glucose Cotransporter-2 Inhibitors (SGLT2i) seem to be beneficial for diabetes and heart 
failure. Clinical efficacy of β-blockers would be suggested from three studies including 
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-
Removing Excess Glucose (EMPA-REG OUTCOME) trial, Canagliflozin cardioVascular 
Assessment Study (CANVAS) and Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure (DAPA-HF) study. Further discussion will be expected with research in detail.
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Table 1 Mega study concerning SGLT2 inhibitors
 EMPA-REG OUTCOME CANVAS Program DAPA-HF
Medicine empagliflozin canagliflozin dapagliflozin
Journal, year N Engl J Med 373:2117 N Engl J Med 377:644 N Engl J Med 381:1995
Authors Zinman B, 2015 Neal B, 2017 McMurray JJV, 2019
Society




European Society of 
Cardiology (ESC)
subjects T2DM with CV CV / high risk DM HFrEF
number 7,020 10,142 4,744
ratio with diabetes 100% 100% 41.80%
HbA1c 8.10% 8.20% N/D
ratio with heart failure 10.10% 14.40% 100%
ejection fraction N/D N/D less than 40%
taking β-blockers in heart failure N/D (total 65.2%) 70.40% 96.00%
reference number 10) 12) 13)
There was a Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure (DAPA-HF) study.14 It was phase 3, placebo-controlled 
trial, and included 4744 patients with New York Heart Association 
(NYHA) class II, III, or IV heart failure, showing an ejection 
fraction (EF) of 40% or less. They are heart failure with reduced 
ejection fraction (HFrEF), including diabetes and non-diabetes, and 
were received either dapagliflozin or placebo. Among them, the 
administration rate of ACE inhibitor/ARB was 80% or more, and 
the β-blocker was administered to almost all cases, in the treatment 
group vs control group as 96.0% vs 96.2%. Diabetes was associated 
with 41.8%, and β-blockers were usually administered. DAPA-HF 
study was different from the former two. DAPA-HF was planned after 
SGLT2i was proved to be effective for heart failure. Therefore, it is 
suggested that the cases with heart failure were probably treated by 
cardiologist, and were prescribed β-blocker already. 
There was a Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) study.15 Totally 2368 cases with both T2DM and 
heart disease were randomly assigned to i) prompt revascularization 
with intensive medical therapy or ii) intensive medical therapy alone. 
It concluded that there was overall no significant difference in the 
rates of death and major cardiovascular events. For this sub-analysis, 
clinical efficacy of β-blocker was investigated.16 Among them, 2244 
T2DM cases were studied, with or without history of myocardial 
infarction (MI)/heart failure (HF). In cases with diabetes and CHD, 
β-blockers showed efficacy in reducing all-cause mortality in those 
with MI/HFrEF(HR 0.60) but not in those without MI/HFrEF (HR 
0.91). From various investigations above, they have recently updated 
elective coronary angiography.17 
In summary, there are some important points as follows: i) Both 
diabetes and heart failure are increasing, ii) β-blockers for diabetic 
seem to be beneficial, but still with controversialdiscussion due to the 
situation, iii) SGLT2i may have effects for diabetes and also heart 
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